Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 13Active not recruiting 8Completed 6Terminated 5Withdrawn 4Unknown 4Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 6Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Sarcoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Colonic Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Burkitt Lymphoma 2Uterine Cervical Dysplasia 1Tongue Neoplasms 1Thrombocytosis 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pruritus 1

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × Biopsy × Clear all
NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

City of Hope Medical Center

Phase 1 Withdrawn
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06730100 2025-10-06

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

City of Hope Medical Center

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05518032 2024-09-26

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

Roswell Park Cancer Institute

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡